Enanta Pharmaceuticals | ENTA - Capitaux D'Emprunt





Capitaux D'Emprunt Changement Date
AbbVie USD 64.53B 5.59B 2026-03
Amgen USD 51.86B 27M 2026-06
Arrowhead Research USD 824.07M 401.34M 2026-06
AstraZeneca USD 26.01B 46M 2026-06
BioCryst Pharmaceuticals USD 395.4M 203K 2026-06
Biogen USD 7.29B 1B 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Enanta Pharmaceuticals USD 0 0 2024-12
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 13.95B 65M 2026-06
Halozyme Therapeutics USD 1.94B 1.79M 2026-06
Heron Therapeutics USD 140.64M 975K 2025-12
Immunic USD 0 0 2024-06
Incyte USD 28.42M 994K 2026-06
Insmed USD 543.51M 1.3M 2026-06
Ionis Pharmaceuticals USD 1.91B 6.62M 2026-06
J&J USD 37.34B 183M 2026-06
Karyopharm Therapeutics USD 264.49M 13.73M 2026-03
Ligand Pharmaceuticals USD 446.9M 704K 2026-03
Merck USD 51.08B 4.41B 2026-06
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.49B 42M 2026-06
Novavax USD 246.3M 200K 2025-12
Pfizer USD 60.5B 70M 2026-06
PTC Therapeutics USD 535.52M 248.58M 2026-06
Roche Holding CHF 25.22B 2.21B 2026-06
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12